文献速递慢阻肺

将缺氧机制转化为慢阻肺长期氧疗处方:一项提议

Translating the Mechanisms of Hypoxia to Long-Term Oxygen Prescription in COPD: A Proposal.
PubMed 文献 · Chest · 2025-06-17

本文基于范围综述提出,仅凭血氧饱和度或动脉氧分压阈值处方长期氧疗可能不恰当。慢性缺氧通过缺氧诱导因子等机制产生适应或不良反应,候选生物标志物(血红蛋白、促红细胞生成素、脑钠肽、内皮素-1、微量白蛋白尿)及基因分型可能辅助个体化氧疗。

要点

  • 长期氧疗处方不应仅依赖Sao2或Pao2阈值,需考虑缺氧适应机制。
  • 候选生物标志物包括血红蛋白、促红细胞生成素、脑钠肽、内皮素-1和微量白蛋白尿。
  • 基因分型可能成为个体化长期氧疗处方的补充方法。

核心结论

  • 仅基于Sao2或Pao2阈值处方长期氧疗可能不恰当。
  • 应优先识别慢性缺氧不良反应的早期指标并验证其用于决定长期氧疗的效用。

研究设计与样本

  • 范围综述,检索文献以识别反映慢阻肺细胞水平缺氧基本机制的生物标志物。

主要发现

  • 慢性缺氧时缺氧诱导因子在细胞核积累上调靶基因,促进耐受。
  • 适应包括过度通气、系统血管床发育、红细胞生成增加和细胞代谢调整。
  • 过度反应可导致肺血管重塑和其他终末器官功能障碍。
  • 候选生物标志物包括循环血红蛋白、促红细胞生成素、脑钠肽、内皮素-1水平及微量白蛋白尿。
  • 缺氧诱导因子血浆浓度用于临床目的目前未充分验证。

关键数值与推荐

  • 当前长期氧疗指征主要基于Sao2或Pao2阈值。
  • 候选生物标志物包括血红蛋白、促红细胞生成素、脑钠肽、内皮素-1和微量白蛋白尿。

临床怎么用

  • 考虑在终末器官功能障碍出现前,结合生物标志物个体化长期氧疗处方。
  • 基因分型可能作为个体化长期氧疗处方的补充方法。

局限性

  • 缺氧诱导因子血浆浓度用于临床目的目前未充分验证。
  • 生物标志物在决定长期氧疗中的效用需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC IMPORTANCE: Current indications for long-term oxygen therapy (LTOT) primarily are based on thresholds of arterial oxygen saturation (Sao2) or Pao2 that ignore fundamental mechanisms of adaptation and intolerance to hypoxia. In individuals exposed to chronic hypoxic conditions, the accumulation of hypoxia-inducible factors in the cell nucleus upregulates target genes that favor tolerance to hypoxia. Adaptations include hyperventilation, systemic vascular bed development, increased erythropoiesis, and cellular metabolic adjustments. Excessive responses to hypoxia also may develop, leading to pulmonary vasculature remodeling and other end-organ dysfunctions. Biomarkers of hypoxia may complement the measurement of Sao2 or Pao2 in personalizing oxygen prescription before end-organ dysfunction becomes clinically apparent. REVIEW FINDINGS: From a scoping review of the literature, we identified several biomarkers that reflect the basic mechanisms of hypoxia at the cellular level in COPD. Although hypoxia-inducible factors are central to these mechanisms, the determination of their plasmatic concentration for clinical purposes currently is not well validated. Candidate biomarkers to guide LTOT prescription include circulating levels of hemoglobin, erythropoietin, brain natriuretic protein, and endothelin-1, as well as macroalbuminuria. Because response to oxygen may be determined genetically, genotyping potentially may serve as an additional method to personalize LTOT prescription. SUMMARY: Prescribing LTOT solely based on Sao2 or Pao2 thresholds may be inappropriate. According to precision medicine principles, we propose that it should be a priority to identify early indicators of adverse reactions to chronic hypoxia and to validate their usefulness in deciding who should receive LTOT.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lacasse Y, Joseph V, Casaburi R, et al. Translating the Mechanisms of Hypoxia to Long-Term Oxygen Prescription in COPD: A Proposal. Chest. 2025. PMID: 40553812. doi:10.1016/j.chest.2025.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。